MedTrace Logo

Efficacy and Safety Study of Aprepitant Injection for Prevention of Post-operative Nausea and Vomiting

NCT06932107 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 518

Last updated 2025-04-23

No results posted yet for this study

Summary

The goal of this Interventional study is to evaluate the efficacy and safety of Aprepitant Injection(QLG2174) for preventing PONV in Chinese patients.

Conditions

  • Postoperative Nausea and Vomiting

Interventions

DRUG

Aprepitant Injection

Before anesthesia induction, 4.4ml(32mg） was given by a single intravenous injection, which was completed within 30 seconds

DRUG

Aprepitant Injection Placebo

Before anesthesia induction, 4.4ml was given by a single intravenous injection, which was completed within 30 seconds

Sponsors & Collaborators

  • Qilu Pharmaceutical (Hainan) Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-02-02
Primary Completion
2024-05-28
Completion
2024-06-05

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06932107 on ClinicalTrials.gov